PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an ...

This was the stock's second consecutive day of gains.

Pfizer Inc. closed $4.65 short of its 52-week high ($31.54), which the company reached on July 30th.

The Nasdaq dropped almost 2% and the S&P 500 lost 1%. Traders see potential for fewer rate cuts this year after the latest ...

The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.

Biotechnology company Atavistik Bio announced Thursday that it has entered into a research collaboration with Pfizer, Inc. (PFE) to ...

Pfizer stock (NYSE: PFE) was up 5% on Tuesday, December 17, after the company announced an optimistic outlook for 2025. The company expects its revenue to be in the range of $61 billion to $64 ...

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

Pfizer projects strong revenue and earnings for 2024 and 2025, with cost-cutting measures aiding financial growth.

Both in their mid-twenties, the two men set up what was initially a fine chemicals business in a Brooklyn factory, using a loan from Pfizer’s father as capital. The company’s first product ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...

"Federal law requires defendants to ensure that their drug labels remain accurate, and when new scientific information ...